BMRN

BIOMARIN PHARMACEUTICAL INC

BMRN·09061G101·US·Common Stock·Healthcare - Biotechnology-13D/G

BMRN (BIOMARIN PHARMACEUTICAL INC) is held by 218 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($1.2B), DODGE & COX ($849.4M), PRIMECAP MANAGEMENT CO/CA/ ($812M). Net institutional sentiment: Mixed.

218
Holders
(18 Elite)
$9.3B
Total Value
51% (223)
Consensus
114 buying - 109 selling
13F: Insider & Congress: Updated regularly
BMRN

Smart Money Verdict

View all
Loading verdict
Held by 218 funds
18 elite

Who's Trading

Source dates: Price Aug 27, 2026 · Insiders May 11, 2026 · Activists Apr 29, 2026 · Congress none

InsiderFRFriberg Gregory RSell $177KMay 7, 2026
ActivistVAVanguard Capital Management5.3%Apr 29, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 26, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
20.4M(+3.2%)$1.2B0.0%+0.76%
33
Increased
14.8M(+1.9%)$849.4M0.4%-17.10%
39
Decreased
14.2M(-0.0%)$812M0.5%-22.52%
0
Increased
8.7M(+1.2%)$500.3M0.0%+16.13%
32
Increased
8.6M(+4.2%)$494.9M0.0%+16.08%
33
Increased
7.8M(+6.9%)$446.4M0.0%-25.20%
33
Increased
7.6M(+7.8%)$435.8M1.2%-10.64%
53
Decreased
5.7M(-25.8%)$322.5M0.1%+7.22%
0
Increased
4.8M(+35.2%)$276M0.0%+12.10%
40
Increased
4.1M(+7.2%)$233.2M0.0%+0.11%
33
Increased
3.9M(+2.4%)$223.9M0.0%-19.08%
31
Increased
3.5M(+0.4%)$200.5M0.0%+12.99%
31
Decreased
2.1M(-31.2%)$118.5M0.0%+7.17%
0
Decreased
1.8M(-8.3%)$100.8M0.1%+9.63%
0
Increased
1.6M(+1.8%)$92.5M0.0%-16.20%
30
Decreased
1.6M(-4.0%)$91.9M0.1%-2.06%
0
Decreased
1.6M(-1.8%)$89.2M0.0%-21.18%
0
Increased
1.5M(+13.9%)$86.1M0.0%+6.39%
34
Increased
1.3M(+66.0%)$75.2M0.1%+2.41%
44
Decreased
1.3M(-14.1%)$73.6M0.0%-4.19%
0

Showing 1-20 of 230

1 / 12
BMRNBMRNBIOMARIN PHARMACEUTICAL INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used